ZDHHC4 and neoplasm: Class II HER2-DC1, when combined with anti-PD-1 antibody, quadrupled the survival rate with increased anti-HER2 CD4+ Th1 immune response and increased CD4+ and CD8+ T cells infiltration within the tumor.